世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の放射能中毒(急性放射線症候群)治療市場 2019-2023年

Global Radiation Syndrome Treatment Market 2019-2023

IRTNTR30225

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年11月US$2,500
シングルユーザライセンス
114

サマリー

この調査レポートは世界の放射能中毒(急性放射線症候群)治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

109 pages, November 2018

About this market


The advent of regenerative therapy is expected to help the market grow. The global radiation syndrome treatment market has seen strong advances in terms of treatment options. The advent of regenerative medicines such as stem-cell therapy is one among such advances. In stem-cell therapy, the stem cells are taken from the patient and are re-inserted to replace the damaged cells to treat or prevent a disease. Technavio’s analysts have predicted that the radiation syndrome treatment market will register a CAGR of more than 6% by 2023.

Market Overview


Increase in nuclear testing
The increasing nuclear testing in South-East Asia in recent years has resulted in the rise in the symptoms of radiation toxicity and exposure in nearby countries. also, various scientists and pharmaceutical companies believe that the increasing testing of nuclear launches cause significant damage to the environment.
Difficult to diagnose
A major share of the global radiation syndrome treatment market is dominated by acute radiation syndrome, which is highly progressive by nature. Acute radiation effects the patients in less than 24 hours of exposure to radiation. The lack of diagnostic devices for radiation syndrome is major challenge faced by the market.
For the detailed list of factors that will drive and challenge the growth of the radiation syndrome treatment market during the 2019-2023, view our report.

Competitive Landscape


The market appears to be fragmented and with the presence of several companies including Amgen and Neumedicines the competitive environment is quite intense. Factors such as the increase in nuclear testing and the advent of regenerative therapy, will provide considerable growth opportunities to radiation syndrome treatment manufactures. Amgen, Neumedicines, Partner Therapeutics, Tonix Pharmaceuticals, and Onconova Therapeutics are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. The market is expected to witness the emergence of many international and regional radiation syndrome therapeutic companies who offer therapeutics for the treatment of HSC syndrome, CNS syndrome, GI syndrome, and cardiovascular syndrome caused by radiation poisoning.’



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY DISEASE
- Market segmentation by disease
- Comparison by disease
- HSC syndrome - Market size and forecast 2018-2023
- CNS syndrome - Market size and forecast 2018-2023
- GI syndrome - Market size and forecast 2018-2023
- Cardiovascular syndrome - Market size and forecast 2018-2023
- Market opportunity by disease
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Amgen
- Neumedicines
- Onconova Therapeutics
- Partner Therapeutics
- Tonix Pharmaceuticals
PART 14: APPENDIX
- Research methodology
- List of abbreviations
PART 15: EXPLORE TECHNAVIO

?
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Disease - Market share 2018-2023 (%)
Exhibit 18: Comparison by disease
Exhibit 19: HSC syndrome - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: HSC syndrome - Year-over-year growth 2019-2023 (%)
Exhibit 21: CNS syndrome - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: CNS syndrome - Year-over-year growth 2019-2023 (%)
Exhibit 23: GI syndrome - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: GI syndrome - Year-over-year growth 2019-2023 (%)
Exhibit 25: Cardiovascular syndrome - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Cardiovascular syndrome - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by disease
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 33: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Amgen - Vendor overview
Exhibit 46: Amgen - Business segments
Exhibit 47: Amgen - Organizational developments
Exhibit 48: Amgen - Geographic focus
Exhibit 49: Amgen - Segment focus
Exhibit 50: Amgen - Key offerings
Exhibit 51: Amgen - Key customers
Exhibit 52: Neumedicines - Vendor overview
Exhibit 53: Neumedicines - Business segments
Exhibit 54: Neumedicines - Organizational developments
Exhibit 55: Neumedicines - Segment focus
Exhibit 56: Neumedicines - Key offerings
Exhibit 57: Neumedicines - Key customers
Exhibit 58: Onconova Therapeutics - Vendor overview
Exhibit 59: Onconova Therapeutics - Business segments
Exhibit 60: Onconova Therapeutics - Organizational developments
Exhibit 61: Onconova Therapeutics - Segment focus
Exhibit 62: Onconova Therapeutics - Key offerings
Exhibit 63: Onconova Therapeutics - Key customers
Exhibit 64: Partner Therapeutics - Vendor overview
Exhibit 65: Partner Therapeutics - Business segments
Exhibit 66: Partner Therapeutics - Organizational developments
Exhibit 67: Partner Therapeutics - Segment focus
Exhibit 68: Partner Therapeutics - Key offerings
Exhibit 69: Partner Therapeutics - Key customers
Exhibit 70: Tonix Pharmaceuticals - Vendor overview
Exhibit 71: Tonix Pharmaceuticals - Business segments
Exhibit 72: Tonix Pharmaceuticals - Organizational developments
Exhibit 73: Tonix Pharmaceuticals - Segment focus
Exhibit 74: Tonix Pharmaceuticals - Key offerings
Exhibit 75: Tonix Pharmaceuticals - Key customers
Exhibit 76: List of abbreviations Error! Bookmark not defined.

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る